We serve DL-Phenylalanine CAS:150-30-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
DL-Phenylalanine
CAS RN: 150-30-1
| Solubility in water | Colorless & clear (c=1) |
| Specific rotation [α]D20 | -0.3°～+0.3°(c= 1, water) |
| Loss on drying | Not more than 0.3% |
| Residue on ignition (as sulfate) | Not more than 0.1% |
| Chloride (Cl) | Not more than 0.02% |
| Sulfate (SO4) | Not more than 0.03% |
| Heavy metals (as Pb) | Not more than 10ppm |
| Iron (Fe) | Not more than 10ppm |
| Ammonium (NH4) | Not more than 0.02% |
| Arsenic (As2O3) | Not more than 1ppm |
| Other amino acids | Not detected by T.L.C.(The spotted amount, 10μg) |
| Assay | 98.5%～101.0% |
Contact us for information like DL-Phenylalanine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DL-.α.-Amino-.β.-phenylpropionic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(±)-2-Amino-3-phenylpropionicacid Use and application,(±)-2-Amino-3-phenylpropionicacid technical grade,usp/ep/jp grade.
Related News: The main API products include antihypertensive, psychotropic and anti-AIDS special APIs. Antihypertensive APIs are mainly pulic and sartan drugs, and they are the world’s major suppliers of pulic and sartan APIs.2-piperazin-1-ylpyrimidine,hydrochloride manufacturer The main API products include antihypertensive, psychotropic and anti-AIDS special APIs. Antihypertensive APIs are mainly pulic and sartan drugs, and they are the world’s major suppliers of pulic and sartan APIs.Propylsulfamide potassium supplier Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.1H,1H,2H,2H-Perfluorooctyltriethoxysilane vendor Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California.“CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.
